What is the gold standard in Coenzyme Q10 clinical studies?

Dr. Svend Aage Mortensen

Dr. Svend Aage Mortensen was the lead researcher on the best clinical trial of CoQ10 supplementation, the Q-Symbio study.

Randomized, double-blind, placebo-controlled clinical trials (RCTs) represent the gold standard method for determining the efficacy and safety of medicinal drugs and nutritional supplements.

What are the gold standard studies of CoQ10 supplementation?

Q-SYMBIO clinical trial

The Q-SYMBIO trial was a multinational, randomized, double-blind, placebo-controlled study investigating CoQ10 as an adjunct to standard treatment for chronic heart failure. The researchers enrolled 420 who received either CoQ10 (3 x 100 mg daily) or placebo for two years. The adjuvant CoQ10 therapy reduced major adverse cardiovascular events at two years (15% vs. 26%) and reduced cardiovascular mortality, all-cause mortality and heart-failure hospitalizations [Mortensen 2014].

KiSel-10 clinical trial

The KiSel-10 trial was a randomized, double-blind, placebo-controlled study involving 443 older adults in Sweden, with a mean age of approximately 78 years. The study participants received CoQ10 (2 x 100 mg/day) combined with selenium-enriched yeast (200 mcg/day) or matching placebos, for four years. The researchers reported improved cardiac function and reduced cardiovascular mortality. Follow-up over 12 years found that cardiovascular mortality remained significantly lower in the supplementation group [Alehagen 2018].

How do RCTs of CoQ10 supplementation work?

To avoid possible study bias in an RCT, the researchers blindly administer the CoQ10 intervention substance to the patients in one group and an identical looking but inactive placebo substance to the patients in the other group. Neither the researchers nor the patients know which patients are receiving which substance during the course of the trial.

What happens if an RCT fails to provide a convincing outcome?

Sometimes, RCTs fail to deliver a conclusive answer. This may happen because the researchers have not recruited enough patients. In such cases, the clinical study is statistically underpowered.

Failure to recruit a sufficient number of patients can occur for a number of reasons. For example, the researchers may have had difficulty in identifying enough eligible participants relevant to a particular medical condition. Similarly, financial constraints, errors in the study planning stage when estimating the extent of the treatment effect, or unexpected numbers patient dropouts can result in an underpowered study.

Why do researchers fall back on meta-analysis?

Sometimes, clinical research generates a number of studies on a particular topic. Individually, the studies are unable to provide a conclusion regarding efficacy and safety. At such times, it is tempting to use the process of meta-analysis.

What is a meta-analysis?

Meta-analysis is a statistical technique for combining data from individual studies on the same topic to form one large dataset. Then, from the large set of data, researchers can draw conclusions about efficacy and safety.

What are the pitfalls of using meta-analysis?

Researchers using the technique of meta-analysis must be aware of potential pitfalls:

  • the possible inferior quality of the data obtained from the individual studies
  • the problem of combining studies with differences in patient populations, dosage regimes, assessment criteria, etc.

Unfortunately, these issues apply to studies involving CoQ10 clinical studies. Thus, meta-analysis of studies on a particular topic involving CoQ10 can be complicated by differences in patient populations and dosage regimes.

What is the biggest problem with some meta-analyses of CoQ10 studies?

By far, the greatest problem occurs whenever the meta-analysis does not take into account the differences in the CoQ10 study preparations supplied by different manufacturers. That is to say, the CoQ10 preparations used in the individual studies can vary greatly in quality and bioavailability.

In addition, the studies included in the meta-analysis may have failed to measure the participants’ baseline and post-treatment blood serum levels of CoQ10. Without these data, the meta-analysis cannot verify if a failed trial was due to CoQ10’s being ineffective or due to the manufacturer’s product never actually being absorbed into the patients’ bloodstream.

Examples of the application of meta-analysis to small-scale CoQ10 clinical studies include the following:

Meta-analysis of CoQ10 and fatigue reduction

In a meta-analysis relating to fatigue reduction, evaluation of thirteen small to medium randomized controlled clinical trials comprising some 1,126 total participants demonstrated a significant reduction in fatigue scores, with higher doses and longer treatment periods correlating with better outcomes (Tsai et al, 2022).

Meta-analysis of CoQ10 and blood pressure

Similarly, a meta-analysis relating to blood pressure comprising seventeen small-scale studies totaling 684 participants found that while individual trials were too small to show clear significance, the pooled meta-analysis revealed a significant decrease in systolic blood pressure for patients with metabolic conditions following CoQ10 supplementation (Tabrizi et al, 2018).

The above two examples provided positive outcomes for the effect of CoQ10 supplementation in particular disorders. However, meta-analysis of CoQ10 studies can also have negative outcomes.

Meta-analysis of CoQ10 and statin treated patients

For example, a meta-analysis comprising six randomized controlled studies and 302 statin treated patients concluded that supplementary CoQ10 did not cause a significant reduction in muscle pain severity (Banach et al, 2015).

Conclusion: Caveat emptor applies to meta-analysis results

Meta-analyses of studies involving CoQ10 supplementation may be flawed because of the inability to take into account the use of CoQ10 supplements provided by different manufacturers in individual studies.

This warning applies whether the CoQ10 meta-analysis has positive or negative outcomes.

Remember, not all CoQ10 supplements deliver equally good absorption and bioavailability. It is important to choose a CoQ10 product with documented effect.

Sources

Alehagen U, Aaseth J, Alexander J, Johansson P. Still reduced cardiovascular mortality 12 years after supplementation with selenium and coenzyme Q10 for four years: A validation of previous 10-year follow-up results of a prospective randomized double-blind placebo-controlled trial in elderly. PLoS One. 2018 Apr 11;13(4):e0193120.

Banach M et al. Effects of coenzyme Q10 on statin-induced myopathy: a meta-analysis of randomized controlled trials. Mayo Clin Proc. 2015 Jan;90(1):24-34.

Mortensen SA, Rosenfeldt F, Kumar A, Dolliner P, Filipiak KJ, Pella D, Alehagen U, Steurer G, Littarru GP; Q-SYMBIO Study Investigators. The effect of coenzyme Q10 on morbidity and mortality in chronic heart failure: results from Q-SYMBIO: a randomized double-blind trial. JACC Heart Fail. 2014 Dec;2(6):641-9.

Tabrizi R et al. The Effects of Coenzyme Q10 supplementation on blood pressures among patients with metabolic diseases: a systematic review and meta-analysis of randomized controlled trials. High Blood Press Cardiovasc Prev. 2018 Mar;25(1):41-50.

Tsai IC et al. Effectiveness of Coenzyme Q10 supplementation for reducing fatigue: a systematic review and meta-analysis of randomized controlled trials. Front Pharmacol. 2022 Aug 24;13:883251.

The information presented in this review article is not medical advice. It should not be used as such.